All In Biotech

Drug Trial Radar · NCT06963827

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 347 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

347

Planned (sponsor's estimate)

Start

Jul 15, 2025

Primary completion

Sep 7, 2028

Study completion Jan 14, 2030

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month. In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.

Conditions

  • Kidney Disease

Interventions

  • MezagitamabDrug

    Mezagitamab injections administered SC.

  • PlaceboDrug

    Mezagitamab-matching placebo injections administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Proteinuria at Week 36Time frame: From Baseline to Week 36

Locations

186 sites in 26 countries. Site status is shown where the registry gives one.

  • UAB Nephrology Research Clinic at Paula Building

    Birmingham, Alabama · Recruiting

  • DCR Montgomery

    Montgomery, Alabama · Recruiting

  • Panoramic Health - Southwest Kidney Institute, PLC

    Surprise, Arizona · Recruiting

  • Panoramic Health - West Coast Kidney Institute (Fremont)

    Fremont, California · Recruiting

  • Academic Medical Research Institute

    Los Angeles, California · Recruiting

  • UCLA University of California Los Angeles

    Los Angeles, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Kaiser Permanente San Francisco Medical Center

    San Francisco, California · Recruiting

  • Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)

    Jacksonville, Florida · Recruiting

  • South Florida Research Institute

    Lauderdale Lakes, Florida · Recruiting

  • Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)

    Melbourne, Florida · Recruiting

  • Bioresearch Partners

    Miami, Florida · Recruiting

  • Total Health and Research Center (THRC)

    Miami, Florida · Recruiting

  • CTR Oakwater, LLC

    Orlando, Florida · Recruiting

  • Bioresearch Partners

    Pembroke Pines, Florida · Recruiting

  • Panoramic Health - Florida Kidney Physicians, LLC (Tampa)

    Riverview, Florida · Recruiting

  • Infigo Clinical Research LLC

    Sanford, Florida · Recruiting

  • DCR Columbus

    Columbus, Georgia · Recruiting

  • Panoramic Health - Southeast Kidney Associates

    East Point, Georgia · Recruiting

  • CARE Institute - Boise Kidney

    Boise, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates

    Rockford, Illinois · Recruiting

  • Northwest Louisiana Nephrology

    Shreveport, Louisiana · Recruiting

  • Ingham Nephrology & Hypertension, P.C.

    Lansing, Michigan · Recruiting

  • Elixia MKC

    Pontiac, Michigan · Recruiting

  • Panoramic Health - Lake Michigan Nephrology, PLC

    Saint Joseph, Michigan · Recruiting

  • DCR Edina

    Edina, Minnesota · Recruiting

  • Elixia MNA

    City of Saint Peters, Missouri · Recruiting

  • Clinical Research Consultants a JCCT Company

    Kansas City, Missouri · Recruiting

  • Renal Medicine Associates - Frenova F1

    Albuquerque, New Mexico · Recruiting

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina · Recruiting

  • Panoramic Health - Kidney and Hypertension Center

    Cincinnati, Ohio · Recruiting

  • Panoramic Health - Clinical Renal Associates, Ltd.

    Media, Pennsylvania · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Panoramic Health - Nephrology Associates, Inc.

    East Providence, Rhode Island · Recruiting

  • Dallas Renal Group

    Dallas, Texas · Recruiting

  • DCR - El Paso

    El Paso, Texas · Recruiting

  • Houston Methodist Research Institute - Department of Medicine

    Houston, Texas · Recruiting

  • Provecta Research Network

    Houston, Texas · Recruiting

  • Nephrology Associates of Houston PLLC

    Katy, Texas · Recruiting

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.